Therapeutic options in neuromyelitis optica spectrum disorders

Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment

(2016) George Tackley et al.   Multiple Sclerosis and Related Disorders

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention

(2015) Dimitrios C. Mastellos et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica

(2015) Wei Qiu et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica

(2015) Shanthi Viswanathan et al.   JOURNAL OF NEUROIMMUNOLOGY

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes

(2015) Maciej Juryńczyk et al.   JOURNAL OF NEUROLOGY

Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up

(2015) L. Piccolo et al.   JOURNAL OF NEUROLOGY

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability

(2015) Hélène Zéphir et al.   JOURNAL OF NEUROLOGY

Placebo studies should not be undertaken in NMO – No

(2015) Benjamin M Greenberg   Multiple Sclerosis Journal

Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders

(2015) Masami Tanaka et al.   Multiple Sclerosis Journal

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

(2015) Dean M. Wingerchuk et al.   NEUROLOGY

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder

(2015) Marius Ringelstein et al.   JAMA Neurology

Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica

(2015) Su-Hyun Kim et al.   JAMA Neurology

Placebo studies should not be undertaken in NMO – No

(2015) Benjamin M Greenberg   Multiple Sclerosis Journal

Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders

(2015) Masami Tanaka et al.   Multiple Sclerosis Journal

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate

(2014) Ramnath Santosh Ramanathan et al.   BMC Neurology

Rheumatoid arthritis medications and lactation

(2014) Lisa R. Sammaritano et al.   CURRENT OPINION IN RHEUMATOLOGY

Safety considerations when prescribing immunosuppression medication to pregnant women

(2014) Maria Gerosa et al.   Expert Opinion On Drug Safety

Patient with Neuromyelitis Optica Spectrum Disorder Combined with Sj^|^ouml;gren's Syndrome Relapse Free Following Tacrolimus Treatment

(2014) Xueping Zheng et al.   INTERNAL MEDICINE

Complement activation in patients with neuromyelitis optica

(2014) Petra Nytrova et al.   JOURNAL OF NEUROIMMUNOLOGY

Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK

(2014) Liene Elsone et al.   Multiple Sclerosis Journal

Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease

(2014) Romana Höftberger et al.   Multiple Sclerosis Journal

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

(2014) D. K. Sato et al.   NEUROLOGY

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study

(2014) M. Araki et al.   NEUROLOGY

Potential Therapeutic Benefit of C1-Esterase Inhibitor in Neuromyelitis Optica Evaluated In Vitro and in an Experimental Rat Model

(2014) Lukmanee Tradtrantip et al.   PLoS One

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies

(2014) Joanna Kitley et al.   JAMA Neurology

Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder

(2014) So-Young Huh et al.   JAMA Neurology

Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica

(2014) Maureen A. Mealy et al.   JAMA Neurology

Efficacy of Intravenous Cyclophosphamide Therapy for Neuromyelitis Optica Spectrum Disorder

(2013) Hiroaki Yaguchi et al.   INTERNAL MEDICINE

Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels

(2013) Su-Hyun Kim et al.   Journal of Clinical Neurology

Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group

(2013) F. Norwood et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies

(2013) J. Kitley et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study

(2013) Sean J Pittock et al.   LANCET NEUROLOGY

Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients

(2013) Liene Elsone et al.   Multiple Sclerosis Journal

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica

(2013) Y. Jiao et al.   NEUROLOGY

Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity

(2013) R. Marignier et al.   NEUROLOGY

Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy

(2013) Ilya Ayzenberg et al.   JAMA Neurology

Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies

(2013) Joanna Kitley et al.   JAMA Neurology

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

(2013) Su-Hyun Kim et al.   JAMA Neurology

Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody

(2012) Lukmanee Tradtrantip et al.   ANNALS OF NEUROLOGY

Treatment of Optic Neuritis by Plasma Exchange (Add-On) in Neuromyelitis Optica

(2012) Harold Merle et al.   ARCHIVES OF OPHTHALMOLOGY

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan

(2012) Joanna Kitley et al.   BRAIN

Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica

(2012) Lukmanee Tradtrantip et al.   FASEB JOURNAL

Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica

(2012) Bhupendra O. Khatri et al.   JOURNAL OF CLINICAL APHERESIS

Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica

(2012) Hiroshi Kuroda et al.   JOURNAL OF NEUROIMMUNOLOGY

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

(2012) Sven Jarius et al.   Journal of Neuroinflammation

Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica

(2012) Takashi Kageyama et al.   JOURNAL OF NEUROLOGY

Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study

(2012) P. Cabre et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders

(2012) Young-Min Lim et al.   Multiple Sclerosis Journal

Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success

(2012) Benjamin M Greenberg et al.   Multiple Sclerosis Journal

Estudio del efecto del tratamiento con inmunoglobulinas por vía intravenosa en la neuromielitis óptica

(2012) M.J. Magraner et al.   NEUROLOGIA

Influence of pregnancy on neuromyelitis optica spectrum disorder

(2012) W. Kim et al.   NEUROLOGY

Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays

(2012) P. J. Waters et al.   NEUROLOGY

Does natalizumab therapy worsen neuromyelitis optica?

(2012) A. Jacob et al.   NEUROLOGY

Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica

(2012) Bernd C. Kieseier et al.   JAMA Neurology

Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica

(2011) Lukmanee Tradtrantip et al.   ANNALS OF NEUROLOGY

A Benign Form of Neuromyelitis Optica

(2011) Nicolas Collongues   ARCHIVES OF NEUROLOGY

Lack of Response to Monoclonal Antibody Therapy in Neuromyelitis Optica

(2011) Peiqing Qian   ARCHIVES OF NEUROLOGY

Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination

(2011) Setty M. Magaña   ARCHIVES OF NEUROLOGY

CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse

(2011) Akiyuki Uzawa et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Impact of rituximab on relapse rate and disability in neuromyelitis optica

(2011) Gurdesh S Bedi et al.   Multiple Sclerosis Journal

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy

(2011) MH Barnett et al.   Multiple Sclerosis Journal

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

(2011) Ju-Hong Min et al.   Multiple Sclerosis Journal

Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica

(2011) C. Costanzi et al.   NEUROLOGY

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

(2011) H. L. Pellkofer et al.   NEUROLOGY

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

(2011) Norio Chihara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neuromyelitis Optica Treatment

(2010) Denis Bernardi Bichuetti et al.   ARCHIVES OF NEUROLOGY

Interferon Beta Treatment in Neuromyelitis Optica

(2010) Jacqueline Palace et al.   ARCHIVES OF NEUROLOGY

Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica

(2010) Su-Hyun Kim et al.   ARCHIVES OF NEUROLOGY

Pregnancy outcomes after maternal exposure to rituximab

(2010) E. F. Chakravarty et al.   BLOOD

Neuromyelitis optica-IgG(+) optic neuritis associated with celiac disease and dysgammaglobulinemia: A role for tacrolimus?

(2010) Isabelle Meyts et al.   EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY

Enhanced IL-6 Production in Aquaporin-4 Antibody Positive Neuromyelitis Optica Patients

(2010) Sema İİçöz et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

The rescue effect of plasma exchange for neuromyelitis optica

(2010) Kai-Chen Wang et al.   JOURNAL OF CLINICAL NEUROSCIENCE

IFN -1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

(2010) J. Shimizu et al.   NEUROLOGY

Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

(2010) Jenny E Higgs et al.   PHARMACOGENOMICS

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

(2010) Jennifer M. Grossman et al.   ARTHRITIS CARE & RESEARCH

Treatment of Neuromyelitis Optica With Mycophenolate Mofetil

(2009) Anu Jacob et al.   ARCHIVES OF NEUROLOGY

Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder

(2009) M Bonnan et al.   Multiple Sclerosis Journal

Treatment of Neuromyelitis Optica With Rituximab

(2008)   ARCHIVES OF NEUROLOGY

Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis

(2008) Patrick Waters et al.   ARCHIVES OF NEUROLOGY